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ABSTRACT
Increased mammographic density (MD) has been shown beyond doubt to be 
a marker for increased breast cancer risk, though the underpinning pathobiology 
is yet to be fully elucidated. Estrogenic activity exerts a strong influence over 
MD, which consequently has been observed to change predictably in response to 
tamoxifen anti-estrogen therapy, although results for other selective estrogen 
receptor modulators and aromatase inhibitors are less consistent. In both primary 
and secondary prevention settings, tamoxifen-associated MD changes correlate with 
successful modulation of risk or outcome, particularly among pre-menopausal women; 
an observation that supports the potential use of MD change as a surrogate marker 
where short-term MD changes reflect longer-term anti-estrogen efficacy. Here we 
summarize endocrine therapy-induced MD changes and attendant outcomes and 
discuss both the need for outcome surrogates in such therapy, as well as make a case 
for MD as such a monitoring marker. We then discuss the process and steps required 
to validate and introduce MD into practice as a predictor or surrogate for endocrine 
therapy efficacy in preventive and adjuvant breast cancer treatment settings.
INTRODUCTION
Breast cancer (BC) is the most common cancer in 
women and the second leading cause of cancer-related 
death among females in the US according to 2016 
statistics [1]. Latest global cancer statistics show that 1.7 
million BC diagnoses and 522,000 BC-related deaths were 
recorded in 2012, with a 20% increase in the BC incidence 
rate and 14% increase in the BC-related mortality rate, 
in comparison with 2008 estimates [2]. Such striking 
statistics highlight the importance of optimizing the 
prevention and treatment of this disease.
Approximately 60-75% of BCs are hormone 
receptor positive, expressing estrogen receptor (ER), 
progesterone receptor (PR) or both [3]. In keeping with 
this, cumulative estrogen exposure has consistently been 
demonstrated to elevate BC risk such that doubling of 
serum estrogen raises BC relative risk by 1.29 fold [4]. 
Factors that modulate estrogen exposure throughout 
life, including endogenous elements such as age of 
                  Review
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menarche and menopause, breast feeding and post-
menopausal obesity, and exogenous elements such as oral 
contraceptives and hormone replacement therapy (HRT), 
all influence BC risk in a direction predictable by their 
impact on estrogen levels [5]. 
Predictably then, endocrine therapy (ET) may be 
used both to reduce the risk of contracting such cancers 
[6, 7] as well as to attenuate the risk of their return after 
surgery for early stage disease [8]. A choice of agents 
needs to be made, particularly between the selective ER 
modulator (SERM) tamoxifen and the aromatase inhibitors 
(AIs), which suppress post-menopausal estrogen synthesis. 
This is in the context of treatment over 5 to 10 years, 
sometimes with significant toxicity and with no method 
of ascertaining whether a particular treatment strategy 
is effective or futile until the advent of BC occurrence/
recurrence or otherwise. For this reason, numerous BC 
biomarkers have been studied to guide both the utility 
of ET overall as well as agent choice, although to date 
only the presence of ER and PR are used to predict overall 
benefit in the clinic and no biomarker guides agent choice. 
On this background, mammographic density 
(MD) shows significant promise as a tool to refine ET 
decisions. MD is an imaging parameter that reflects the 
relative amounts of various tissue elements in the breast. 
It is well established that radiographic MD histologically 
corresponds to higher fractions of stroma and epithelium 
relative to adipose tissue [9]. It has also been demonstrated 
to correlate directly and incrementally with BC risk [10] in 
such a way that for every 3-6% MD rise, relative BC risk 
increases by 10% [11]. In addition to demonstrating utility 
in predicting the initial risk of BC [12], MD at diagnosis 
also correlates with subsequent risk of local but not distant 
relapse [13].
Higher MD, which correlates with increasing BC 
risk, has been documented in post-menopausal women 
receiving exogenous estrogen as a replacement therapy 
[14, 15], as well as among non-HRT users with higher 
levels of endogenous estrogen [16]. In addition, more 
frequent expression of ERα has been found in the stroma 
of the risk-associated higher MD mammary tissue [17]. 
Thus, an intrinsic causal link appears likely within this 
triad of higher estrogen activity, high MD and elevated 
BC risk. It therefore follows that gaining a greater 
understanding of the underlying pathobiology linking 
MD and BC, and how estrogens and anti-estrogens may 
broker that link, could give us new insights into improved 
therapeutic approaches against the disease beyond 
prediction of risk.
As defined by the Biomarker Definition Working 
Group of the National Institute of Health, USA, a 
biomarker is any objectively measurable characteristic that 
could indicate an underlying physiological or pathological 
process (e.g. BC risk) or evaluate the response to an 
intervention (e.g. ET) [18]. Two concepts should be 
distinguished, that of a prognostic marker, which informs 
about the native risk of certain outcomes in the absence 
of any intervention, to be differentiated from a predictive 
marker which predicts response to an intervention [19]. 
Importantly, the FDA considers surrogate markers in 
the approval process, measurable parameters that may 
be used as a substitute for clinically relevant endpoints 
in interventional trials, essentially synonymous with 
predictive markers [20]. For a biomarker to be validated 
as “predictive”, correlation with outcome needs to be 
evaluated in clinical trials treating the disease where the 
intervention is randomly allocated to the subjects, ideally 
with the biomarker study forming part of the prospective 
design [21]. A control group is essential for full predictive 
biomarker evaluation, excluding the possibility that 
correlations between biomarker and outcome are not 
purely due to a prognostic effect.
There is a surfeit of commonly employed prognostic 
biomarkers used to gauge the risk of both BC incidence, 
such as family history and prior breast biopsy [22]; or 
relapse, such as lymph node involvement, size and grade 
of tumour [23]. In contrast, there is a dearth of predictive 
markers for ET efficacy in these scenarios. In addition to 
data indicating predictive ability, a potential biomarker 
that could indicate ET efficacy would ideally fulfil the 
following criteria: 1) biologically plausible [24], that is an 
intrinsic link to BC therapeutic biology would account for 
the prediction of ET-mediated protective effect, 2) serially 
measurable, such that it can be practically used to indicate 
whether the ET-mediated risk-modifying process is 
proceeding in a favourable way relatively early in therapy, 
when tailoring of the preventive intervention can still be 
undertaken i.e. before BC occurrence or recurrence, and 
3) applicable to both the preventive and adjuvant settings.
Immunohistochemical (IHC) biomarkers such 
as ER expression [25] and STAT5 expression [26] are 
indeed helpful for deciding which patients may benefit 
from ET on pathogenesis related grounds and thus fulfil 
criterion 1, although they do not provide guidance on ET 
agent choice. However, being inherent characteristics 
of the initial tumour, such biomarkers are not useful as 
monitoring tools as change cannot be measured to reflect 
ET action and they are not useful in the preventive 
setting as there is no actual tumour to assess. Although 
MD has plausible biological links to breast cancer risk 
(criterion 1), unlike these biomarkers it cannot be used to 
specifically select patients likely to benefit from ET prior 
to treatment in the adjuvant setting. In contrast, however, 
MD may be measured through the treatment period, with 
MD change potentially reflecting ET efficacy (criterion 
2). Additionally, being a character of the “breast” rather 
than the “tumour” with pathogenic links to BC risk, 
MD change may be used to predict ET efficacy in the 
preventive setting (criterion 3) and serial monitoring of 
the unaffected breast maintains MD utility in the adjuvant 
setting after surgical excision of the cancerous breast 
tissue (criterion 3). Thus, MD is intuitively a compelling 
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biomarker for monitoring the response to ET in patients 
selected for therapy. Such therapy may be dictated by MD 
stratification of risk in primary prevention and according 
to ER and PR status in the adjuvant setting. 
In this article, we have reviewed the MD changes in 
relation to the spectrum of ETs employed in different BC 
scenarios to explore whether evidence to date supports this 
hypothesis and, if this proves to be the case, to ascertain 
what further research is required to bring this into routine 
practice. Specific aims of the review are to:
1) Look at degree and timeframe of MD change 
with currently employed ETs.
2) Assess the utility of serial MD measurements 
for predicting the primary preventative benefit of 
chemoprophylaxis in females with elevated BC risk.
3) Assess the effectiveness of serial MD 
measurement in the follow-up of females with surgically 
excised early breast cancer on adjuvant ET to prevent 
recurrence.
4) Explore the mechanisms connecting MD 
with breast cancer risk and prevention to identify new 
biological avenues of protection from adverse breast 
cancer outcomes.
Table 1: Studies investigating MD changes in response to use of SERMs
Study Subjects
Protocol Results (PMD Change)
Mammography
Agent and dose
Time
N
PMD (%) p value
Reference Trial Type
Age (yr) On
Baseline Finish versusbaseline
versus
controlClinical 
Scenario Measure
Post-
Start Therapy
Tamoxifen
Brisson
2000[28] RCT
≥35
Prevention
PMD,
Wolfe 41 m
Placebo
Tamoxifen 20mg 60 m
33
36
60.5
60.3
51.1
56.7
NR
NR
NA
0.01
Chow
2000[29] RCT
36-74
Prevention
PMD
Boyd, 
BIRADS
22 m ControlTamoxifen 20mg 24 m
20
27
29.7
31.9
29.6
29.2
0.88
0.0007
NA
NR
Konez
2001[31]
Retro
cohort
31-81
Adjuvant 
post-BC
MD
Category 60 m Tamoxifen 20mg 60 m 24 20.8%* 0.06 NA
Cuzick
2004[27] RCT
35-70
Prevention
PMD,
Boyd 54 m
Placebo
Tamoxifen 20mg 60 m
430
388
42.6
41.9
35.3
28.2
<0.001
<0.001
NA
<0.001
Meggiorini
2008[30]
Retro
cohort
41-78
Adjuvant 
post-BC
BIRADS 12 m ControlTamoxifen 20mg 60 m
80
68
30%*
50% *
NR
NR
NA
0.021
Howell
2015[33]
Retro
cohort
33-46
Prevention PMD 12 m Tamoxifen 12m 105 49%
† NR NA
Engman
2016[32]
Retro
cohort
45-60
Adjuvant 
post-BC
VPD,
DV annually Tamoxifen 36 m 379
11.6
64.7
17%**
0,90**
NR
NR
NR
NR
Raloxifene
Freedman
2001[39] RCT
45-60
Prevention
Post-
menopause
PMD 24m
Placebo
Raloxifene 60mg
Raloxifene 150mg
24 m
45
45
42
9.8
9.3
8.1
8.5
7.7
6.4
<0.02
<0.02
<0.02
NA
NS
NS
Christo-
doulakos
2002[38]
RCT
41-67
Risk of 
osteoporosis
Wolfe 12m
Placebo
Raloxifene 60 mg
Tibilone 2.5mg
12 m
27
48
56
25.9 †
18.8†
10.7†
0 ††
6.3 ††
10.7 ††
NR
NR
NR
NA
0.47
0.07
Cirpan
2006[37]
Retro
cohort
43-58
Osteoporosis BIRADS 12m Raloxifene 60mg 12 m 55
MD category increase 
in one patient. 
Otherwise, no change
0.32 NA
Eng-Wong
2008[40] CT
35-47
Prevention PMD 24 m Raloxifene 60mg 24 m 27 38 41.5 NS NA
Eilertsen
2008[36] RCT
45-65
Prevention
PMD 
(volume) 12 week
Raloxifene 60 mg
Low dose HRT
Standard dose HRT
12 week
44
44
45
7.7
8.6
8.3
8.1
11.2
10.6
0.09
<0.0001
<0.0001
NA
NA
NA
Nielsen
2009[35] RCT
55-80
Risk of 
osteoporosis
PMD
BIRADS 24m
Tibolone
Raloxifene 60 mg
Estradiol 0.014 wk,
24 m
45
135
135
7.5
16
16
8.1
18
20
0.9
NS
<0.05
NA
NA
NA
Harvey
2013[34] RCT
40-75
Risk of 
osteoporosis
PMD 24m
Placebo
BZA 20mg/E 0.45mg
BZA 20mg/E0.625 mg
Raloxifene 60 mg
24 m
126
129
105
125
26.1
26.5
25.3
27.2
25.7
26.1
25.2
27
significant
significant
NS
NS
NA
NS
NS
NS
* % pts with MD category reduction, † % pts with MD decrease,  **annualized MD reduction, †† % pts with MD increase
RCT: Randomised Controlled Trial, Retro cohort: Retrospective cohort, BC: Breast Cancer, PMD: Percent Mammographic 
Density, BIRADS:  Breast Imaging-Reporting and Data System, VPD: Volumetric Percent Density, DV: Dense Volume, 
m: month, HRT: Hormone Replacement Therapy, BZA: Bazedoxifene, NS: Not Significant, NR: Not Reported, NA: Not 
Applicable
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RESULTS
MD change on currently employed ET
A total of 19 publications recorded MD changes 
across periods of ET. Table 1 summarizes MD changes 
on SERMs. With regards to the seven studies exploring 
changes on tamoxifen, all of which were in populations 
including pre-menopausal women [27-31], by far the 
largest study was the IBIS I prevention study accounting 
for more than two thirds of patients. Significant reductions 
in all sub-groups were seen on tamoxifen relative to 
placebo; 7.9% v 3.5% at 18 months (p < 0.001) and 
13.7% v 7.3% at 54 months (p < 0.001) [27]. The three 
other trials with placebo or control arms [28-30] all 
showed significant MD reductions on tamoxifen despite 
low participant numbers. Two other recent retrospective 
studies have also demonstrated an annual MD reduction 
in tamoxifen-treated women [32, 33]. Of interest, the 
small single study looking at subsequent MD change after 
tamoxifen completion showed small increases in MD post-
tamoxifen in 48% of cases, albeit of unknown prognostic 
significance [31].
For the alternative SERM raloxifene, six of seven 
studies have been in post-menopausal patients [34-39]. 
Although numbers have been low, and comparisons 
sometimes made with patients on HRT rather than 
placebo [36], none have shown significant MD changes 
relative to placebo or baseline in single arm trials. Further, 
two studies have shown trends to increases rather than 
decreases of MD on the drug [35, 38]. The single pre-
menopausal study showed no impact of raloxifene on MD 
[40]. In keeping with this the head-to head STAR trial, 
comparing tamoxifen to raloxifene for primary prevention 
showed a significant modestly inferior protection with 
raloxifene compared to tamoxifen, although whether 
individuals experiencing an MD increase responded 
poorly is unknown [41].
Despite the proven therapeutic efficacy of aromatase 
inhibitors (AIs) in the adjuvant setting [42], MD has not 
been observed to change consistently or significantly in 
response to these agents (Table 2). Of six relevant studies, 
three uncontrolled studies showed MD reductions with 
two reaching significance [32, 43, 44]. Three further trials 
with control arms demonstrated no MD reduction relative 
to untreated patients, although numbers in all trials were 
low [45-47]. To summarize, contrary to the case with 
tamoxifen, a convincing case for using MD to monitor the 
effects of AIs and other SERMs is not evident from this 
assembled data.
Correlations between MD change and primary 
prevention efficacy
From our review of the data, only one study has 
directly linked tamoxifen-induced MD reduction to the 
subsequent risk of developing BC; the report of Cuzick 
and colleagues on a nested study from the IBIS I trial 
of tamoxifen versus placebo in women at high risk of 
the disease [48]. Here they report a significant 63% BC 
risk reduction among tamoxifen users having greater 
than 10% MD reduction (MDR), compared to no risk 
reduction if MDR was less than 10% (odd ratios: 0.37 vs. 
1.13), as assessed visually in 12-18 month post-treatment 
mammograms [48, 49]. No literature was identified 
Table 2: Studies investigating MD changes in response to use of AIs
Study Subjects
Protocol Results (PMD Change)
Mammography
Agent and dose
Time
N
PMD (%) p value
Reference Trial Type
Age (year) On 
Baseline Finish versusbaseline
versus
controlClinical Scenario Measure Post-Start Therapy
Vachon
2007[45] RCT
30-84, post-
tamoxifen
Adjuvant post-BC
PMD 12 m Placebo Letrozole 2.5 mg 60 m
33
35
20
18.5
19
16.9
NR
NR
NA
0.58
Cigler
2010[46] RCT
Post-menopausal
Prevention
PMD
Boyd, BIRADS 24 m
Placebo
Letrozole 2.5mg 12 m
16
27
40
39.6
38.7
39.6
0.71
0.99
NA
0.69
Cigler
2011[47] RCT
Post-menopause
Prevention
PMD
Boyd, BIRADS 12 m
Control
Exemestane 25mg 12 m
31
34
36.5
33.9
37.1
34.5
NR
NR
NA
0.91
Smith
2012[43] CT
Mean 58.9
Prevention PMD 12 m Letrozole 2.5mg 12 m 16 27.7 23 0.036 NA
Gatti-Mays
2016[44]
Phase II
trial
Post-menopausal
Prevention PMD 24 m Exemestane 25mg 24 m 35 32.5 28.4 0.009 NA
Engman
2016[32]
Retro
cohort
58-71
Adjuvant post-BC
VPD
DV annually AIs 36 m 425
7.2
51.9
0.19%*
0.52*
NR
NR
NR
NR
*annualized MD reduction
RCT: Randomised Controlled Trial, Retro cohort:  Retrospective cohort, BC: Breast Cancer, PMD: Percent Mammographic 
Density, BIRADS:  Breast Imaging-Reporting and Data System, VPD: Volumetric Percent Density, DV: Dense Volume m: 
month, NR: Not Reported, NA: Not Applicable
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regarding MD change in the IBIS II [7] or MAP.3 [42] 
studies, which have employed anastrozole and exemestane 
respectively versus placebo for primary BC prevention. 
Howell et al subsequently reproduced this spectrum of MD 
changes on preventative tamoxifen, though highlighted 
the difficulty of assessing MD consistently in general 
radiological practice and suggested introducing volumetric 
methods for clinical usage [33]. 
Correlations between MD change and adjuvant 
ET benefit
Before reviewing the predictive impact of MD 
change on adjuvant ET efficacy, it is worthwhile to 
consider first the prognostic impact of MD baseline 
present at the time of BC diagnosis. A lower MD has 
been reported in most studies to be linked to better BC 
outcomes in terms of lower risk of local recurrence [13, 
50], death from all causes [51] and risk of second BC 
[52], although none have shown a significant association 
to the risk of distant metastasis or BC-specific mortality. 
Baseline MD is thus prognostic for certain parameters of 
outcome.
Turning to the prediction of ET benefit in the 
adjuvant setting, seven studies have directly assessed 
BC outcome measures in relation to ET-induced MD 
changes (Table 3). Three case-control studies [53-55] and 
three retrospective cohorts [56-58] have demonstrated an 
association between MD reduction in response to ETs and 
better BC outcomes, in terms of BC-related death, BC 
recurrence and contra-lateral primary. Risk reductions 
were uniformly significant and robust for disease free 
survival (DFS) (0.36-0.52) and overall or BC specific 
survival (0.44-0.50), although these trials involved mostly 
tamoxifen and were mostly in younger women. One 
study failed to demonstrate an association between MD 
reduction and lowering of recurrence events in response 
to exemestane or tamoxifen in post-menopausal women, 
although the MD changes were small [59]. Contrary to 
this, the studies of Kim et al [57] and interim analysis of a 
study by members of our group [58], found MD reduction 
to be a predictor of outcome in mixed tamoxifen and AIs 
treated cohorts.
Findings from these studies suggest that MD change 
could be a valuable biomarker for predicting the impact 
Table 3: Studies investigating BC risk/outcome modification in relation to ET-induced MD changes
Study Subjects Protocol Results
Reference Type
Age (yrs) 
Menopausal 
status
Mammography
Event Medication N
BC-Related Outcomes
Method Time on Rx
MD Change 
Categories
HR                   
(MDR v 
not)
95% 
CI p
Preventive - Women at high BC risk
Cuzick
2011[48]
Case 
cont
within 
RCT
35-70
Mixed
PMD
(PDA) 12-18m
MDR ≥10%
v no decrease BC risk Tamoxifen 507 0.32 0.14-0.72 0.001
Adjuvant – Hormone receptor positive early breast cancer
Kim
2012[57]
Retro 
cohort
25-78
Mixed PMD 13 m
MDR ≥ 10%
v MDR < 0% BCR
Tamoxifen
or AI
1065
(938 
invasive)
0.44 0.22-0.91 0.027
Ko
2013[56]
Retro 
cohort
25-78
Mixed BIRADS 19 m
MDR by 1+ 
BIRAD category
v no change 
BIRAD category
BCR Tamoxifen
1066
(932 
invasive)
0.36 0.18-0.70 0.003
Li
2013[54]
Case 
cont
Median 62-63
Post-
menopause
ADA 17 m MDR > 20%v MDR < 10% BCSM Tamoxifen 474 0.5 0.27-0.93 0.017
Sandberg
2013[55]
Case 
cont
NR
Post-
menopause
PMD 19 m MDR ≥ 10%v MDR < 10%
CBC 
risk Tamoxifen 87 0.52 0.18-1.51 NS
Nynate
2015[53]
Case 
cont
32-87
Mixed
PMD
(PDA) 12m
Tertiles highest 
MDR (>8.7 %)
v lowest MDR 
(<0.5 %)
BCSM Tamoxifen 349 0.44 0.22-0.88 0.005
Martin
2015[58]
Retro 
cohort
25-96
Mixed PMD 11-24 m
MDR > 20%
v MDR < 0% BCR
Tamoxifen
or AI 921 0.45 0.25-0.80 0.006
Van Nes
2015[59]
Retro 
cohort
within 
RCT
45-91
Post-
menopause
PMD
(PDA) 24 m
Pts divided into 6 
categories
No density change 
on Rx
BCR
Tamoxifen 
or
Exemestane
377
NR
No 
density 
change
NR NR
RCT: Randomised Controlled trial, Retro cohort: Retrospective cohort, MDR:  Mammographic Density Reduction, PMD: 
Percent Mammographic Density, BIRADS:  Breast Imaging-Reporting and Data System,PDA: Percent Dense Area, ADA: 
Absolute Dense Area, BCSM: Breast Cancer Specific Mortality, BCR: Breast Cancer Relapse, CBC: Contralateral Breast 
Cancer, AI: Aromatase Inhibitor, HR: Hazard ratio NR: Not Reported
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of adjuvant tamoxifen on ER positive BC outcomes in 
younger women, with more heterogeneous evidence in 
older post-menopausal women, particularly those on AIs.
Biological processes underlying MD change, BC 
risk and ET action
Recent genetic studies have identified certain single 
nucleotide polymorphisms (SNPs) with overlapping 
effects on both BC risk and MD, suggesting that the BC 
risk conferred by these loci is at least partly mediated 
through their effects on MD [60]. Polymorphisms of 
genes involved in epidermal growth factor (EGF), ER 
and insulin-like growth factor 1 (IGF1) signalling, 
cell proliferation, and migration are included [61]. 
Furthermore, MD changes in perimenopausal women 
of different racial descents have been linked to SNPs in 
genomic loci encoding enzymes controlling sex steroid 
metabolism and ERs. Since the former act upon and the 
latter are expressed in breast tissue, such SNPs could 
therefore impact BC risk through MD modulation via the 
estrogen/ER interaction [62]. Additionally, recent analysis 
of known BC susceptibility genes has identified two novel 
MD loci in 6q25.1 region, one of which is in the TAB2 
gene [63], a potential driver of tamoxifen resistance [64]. 
Reduced tamoxifen effectiveness, mediated through these 
loci, may explain the higher risk of local relapse and 
contralateral primary BC associated with higher MD.
Turning to potential proteomic drivers of risk, high 
MD tissue shows higher expression of proteins involved 
in angiogenesis, inflammation, proliferation and estrogen 
synthesis, whereas low MD tissue shows higher expression 
of effectors of cell cycle arrest and estrogen inactivation 
[65]. Fibrous stroma of women at high risk of BC was 
noted to very frequently express ERα regardless of MD 
status, whereas frequent expression of PRα was found in 
the stroma of high MD compared to low MD mammary 
tissue, and is thus also pathogenically implicated [17].
Considering mammographically dense tissue from 
the perspective of whole tissue cellular interactions, the 
influence of MD on breast cells at risk, roles of stromal 
cells that appear to confer risk, and adipose cells that may 
confer protection are key questions [60].
Tamoxifen is the most extensively studied ET in 
both preventive and adjuvant settings for BC and also the 
drug with the most consistent links between induced MD 
change and BC. Therefore, it is worthwhile reviewing 
the established and possible mechanisms through which 
tamoxifen could impact both MD and BC. In terms 
of tamoxifen effects on breast tissue, the drug was 
noted to cause a reduction in the stromal component of 
biochamber-implanted HMD tissue, which was associated 
with reduction of MD [66]. In addition to contributing to 
an HMD status [67], a high stromal density contributes 
to a higher BC risk in animals [68, 69]. Thus, tamoxifen-
induced reduction of stromal density could reduce BC 
risk concomitantly with its demonstrated MD lowering 
effect. Similarly, a reduction in the absolute epithelial 
mass has been observed in response to tamoxifen 
treatment in rodents. Such reduction was concomitant 
with MD reduction [70] and possibly with lower BC 
events. Additionally, the proliferative state of epithelial 
cells may affect both MD and the probability of cancer-
initiating genetic damage [71]. However, the role of 
tamoxifen-mediated reduction of stromal and epithelial 
components in causing reduction of MD-associated 
breast carcinogenesis is speculative and needs further 
confirmatory studies.
Looking at specific signalling pathways, a number 
of pathways that mediate the pathogenesis of BC and 
MD have been identified as targets for tamoxifen action. 
Tamoxifen has been reported to enhance expression of 
transmembrane receptor CD36 [72], which was found 
to be repressed both in HMD tissue and in BC [73]. 
Suppression of Hedgehog signalling in response to 
tamoxifen has been demonstrated to remodel the stromal 
micro-environment [74] through down-regulation of 
stromal fibroblast proliferative activity [75]. A higher 
proliferative rate of stromal fibroblasts has been implicated 
in HMD status [76] and higher rate of cancer initiation as 
well [77]. Tamoxifen was also reported to interfere with 
IGF1 receptor (IGF-1R) signalling [78]; the expression of 
which has been found to increase in relation to both BC 
and increased MD [79, 80]. Similarly, tamoxifen has been 
known to reduce circulating IGF-1 [81], which was found 
to positively correlate with both BC risk [82] and HMD 
[83]. Furthermore, tamoxifen treatment of biochamber-
implanted HMD tissue has been shown to alter Cox-2 
expression in stromal cells [84], which has been found 
in other studies to be implicated in both MD and tumour 
initiation [85], adding another possible mechanism of 
tamoxifen reduction of MD and associated BC events.
DISCUSSION
MD modification on ET
Across the spectrum of available studies tamoxifen 
has been shown to reduce MD in a significant proportion 
of participants, which has allowed further analysis of these 
changes in relation to efficacy. The degree and direction 
of change on raloxifene is more heterogeneous with 
significant MD reduction not being seen in any study. 
Whether this represents a subtly different mechanism 
of action or lower potency and efficacy, as suggested 
by the previously referenced STAR trial, is unclear. 
Significant MD changes on AIs have not been frequently 
observed; which could suggest that AIs may exert their 
therapeutic effect through non-MD mediated mechanisms. 
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Additionally, as AIs are only indicated as single agents 
in the postmenopausal setting where baseline MD tends 
to be low, this may also explain why their effects on MD 
are not significant. In keeping with this, most studies 
have observed that MDR was more substantial in women 
having initially higher MD [27, 86, 87]. Whether a longer 
period of observation is useful to capture more significant 
change is unknown, although a significant prolongation of 
time to acquisition of a usable efficacy prediction would 
obviously diminish clinical utility.
MD change in premenopausal women
Both the likelihood and the magnitude of ET-
induced MD reduction have been universally observed 
to be greater among pre-menopausal women, at least 
in part due to their higher baseline MD at study entry 
time, which is attributable to higher ovarian estrogen 
production. Additionally, pre-menopausal women are 
generally younger and tend to be more physically active, 
thus possibly having lower BMI. Both factors, younger 
age [56] and lower BMI [27], have been demonstrated 
in multivariate analysis to be significant independent 
predictors of greater MD reduction. It is thus expected 
that the potential for MD change as an ET-monitoring tool 
would be greatest among this subgroup of women. 
MD as a predictive surrogate in primary 
prevention
The uptake of tamoxifen in primary prevention by 
women at high risk of BC is low with less than 5% of 
high risk women utilising this approach [88]. Confirmation 
of the provocative findings relating to MD change and 
benefit seen in IBIS I in a second study utilising tamoxifen 
would assist in bringing MD assessment into clinical 
practice and could significantly improve preventative 
tamoxifen uptake. The optimal trial design would 
explore a strategy of continuation or discontinuation of 
preventative treatment based on MD change relative to 
continued therapy regardless of MD alterations, and would 
measure subsequent BC risk. Extension of research into 
prevention studies employing AIs such as IBIS II [7] or 
MAP.3 [42] would both clarify the role of MD change 
with this class of agent and add a valuable prediction tool 
across the future BC prevention landscape. If positive, 
this could particularly guide personalised prevention 
allowing tailoring towards the most effective agent for the 
individual; SERM or AI.
MD modulation in adjuvant studies
Considering the observations that initial MD can 
predict the risk of second primary and local relapse, 
this supports the hypothesis that tamoxifen-induced MD 
reduction may, at least in part, reflect improvements in 
BC outcome through modulation of the effects of the local 
breast environment on developing or residual malignant 
cells.
Across the adjuvant tamoxifen studies, particularly 
in younger women, the predictive power of MD change 
appears consistent and robust. However, all studies 
to date have failed to account for important potential 
confounders. An important example of such confounders 
is chemotherapy treatment, which frequently induces 
menopause in treated pre-menopausal patients. The 
resultant reduction in ovarian hormonal output can 
significantly improve BC outcomes, as most recently 
evidenced by the SOFT trial in women still pre-
menopausal after chemotherapy [89], and would also be 
expected to bring about a reduction in MD. In this regard it 
is noteworthy that the two largest studies by Kim et al [57] 
and Ko et al [56] had mean ages of 49 and 45 years and 
chemotherapy delivery rates of 77% and 68% respectively, 
suggesting that chemotherapy-induced menopause 
would have been a frequent occurrence. Chemotherapy-
induced menopause should, therefore, be accounted for 
in correlative analyses of MD reduction and protective 
benefit to exclude this confounder as the driver of MDR-
protective benefit correlation. Furthermore, older women 
ceasing hormone replacement therapy (HRT) at diagnosis 
could also experience prognostically important MD falls 
independent of ET effect. Interim analysis was recently 
presented of research undertaken by members of our group 
examining the predictive power of MD fall in the first 921 
patients of a 1942 adjuvant ET-treated retrospective cohort 
[58]. Full data on chemotherapy-induced menopause and 
HRT cessation are available for this study cohort and will 
be factored into the final analysis.
The value of MDR as a predictor of AI efficacy 
is less clear. In the larger retrospective study of Kim et 
al [57], MDR had similar predictive power for AI and 
tamoxifen usage. The study by members of our group 
mirrored this; patients on tamoxifen and AIs experienced 
numerically close MDRs, which have been subsequently 
found to correlate significantly with DFS in the entire 
cohort, suggesting therefore that MDR could be predictive 
of AI efficacy as well. The detailed results however are 
yet to be reported in the final analysis [58]. In contrast, in 
the study of Van Nes et al of patients from the prospective 
TEAM study, infrequent MDRs and a lack of correlation 
with outcome were observed [59]. The reason for this 
heterogeneity is unclear. The most common AIs in 
general use, and used in the study of Kim et al, are the 
non-steroidal AIs (NSAIs) letrozole and anastrozole. In 
contrast, the negative study [59] employed exclusively 
exemestane. Inter-agent differences in effect on MD are 
thus a possibility although efficacy differences have not 
been seen in head-to-head trials between AIs. Exploring 
alternative explanations, it is noteworthy that 77% of 
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patients in the study of Kim et al received chemotherapy 
and thus a proportion of patients may have received an 
AI following on from chemotherapy-induced menopause, 
a time at which MD often falls. Again in contrast, 
the TEAM study required patients to have confirmed 
menopause at study entry and hence may have been further 
from menopause with consequently lower MD, making 
resultant changes smaller on treatment. Additionally, high 
BMI can confound AI efficacy and also interact with MD. 
On the TEAM study, 61% of this older European-derived 
patient population was overweight or obese. BMI was not 
reported in the study of Kim et al, but might be expected 
to be significantly lower in a younger Korean population, 
raising the possibility that BMI might differentially 
modulate AI efficacy and explain inter-trial MD change 
discrepancies. Contrary to this, the BMI demographic in 
the Australian study by members of our group was more 
reflective of the TEAM population with 65% overweight 
or obese but still showing measurable MD falls in the 
entire cohort, including those on AIs.
It is also worth considering the biology behind the 
association between MDR and BC outcome, particularly 
for distant relapse [56, 57] and mortality [53, 54] in the 
adjuvant setting. Here, presumptive micro-metastases are 
established prior to definitive surgery in non-breast tissues. 
MD change could either be a specific surrogate for the 
influence of ET on non-breast tissues or a broader surrogate 
for favourable pharmacokinetics such as increased drug 
activation, longer retention or reduced deactivation. On the 
former point, there is little cancer-specific data although 
estrogen and anti-estrogens are well known to influence 
bone biochemistry, a common metastatic site. On the latter 
point, a clinically relevant possibility is that MD change 
may predict tamoxifen activation status. Cytochrome P450 
2D6 enzyme (CYP2D6) metabolizer status influences 
such activation, with poor metabolisers (PMs) showing a 
degree of tamoxifen resistance. Extensive metabolizers, 
rather than PMs, were more likely to have a greater 
than 10% MD reduction in 12 month post treatment 
mammogram [90] and have been found in some studies to 
have improved outcomes [91], although results have been 
inconsistent, possibly due to molecular heterogeneity in 
other tamoxifen-metabolising enzymes [92]. As a potential 
marker of tamoxifen activation, MD change bypasses the 
need both for a detailed understanding of and complex 
testing for such enzyme variants.
Insights from the pathobiological links between 
MD, BC risk and ET action
Reassuringly, a number of known mechanisms 
of pathogenic importance to BC have been found to be 
interlinked with MD, including key signalling pathways, 
enhancers of motility, angiogenesis and inflammation, 
which further validate MD as intrinsic to BC development. 
The identification of specific molecules within these 
functional domains may indicate that these molecules are 
particularly important to oncogenesis and thereby, could 
elevate them to suitable drug targets. For example, the 
TAB2 protein is implicated in disrupting co-repressor 
binding to ERs in response to tamoxifen, preventing 
tamoxifen-driven transcriptional suppression [64]. 
High MD and BC risk linked to polymorphisms in this 
molecule may arise from an impact on the co-repressor:co-
activator balance in normal health, increasing the impact 
of estrogens on normal tissues including the breast [63]. 
Attenuating this function could be explored in prevention 
and treatment in women with high MD.
MD evaluation modalities and radiation exposure
Various imaging modalities have been developed to 
evaluate MD, among which X ray-based and MR-based 
modalities are the best established [93]. On the balance 
of cost effectiveness and measurement efficiency, digital 
mammography (DM) is the most commonly utilized in 
clinical practice, with continuous advancement in MD 
measurement software. Although the involved radiation 
risk is generally small, the issue becomes a concern when 
taking into account that the mammographic examination 
is taking place in basically asymptomatic woman in the 
preventative setting. A recent study by Al Kattar et al 
[94] demonstrated that the mean glandular radiation dose 
(MGD) delivered from DM as measured in a standard 
breast phantom was at most 2.05 mGy at an average 
thickness of 50mm, which is far less than maximal MGD 
accepted in the AFSSAPS 2006 report and FDA allowable 
limit of 3 mGy per exposure [95]. From a clinical 
perspective, the lifetime risk of BC incidence attributed to 
2D bilateral screening mammography in 40 year woman 
has been estimated to be 5-7/100000 [96].
Is MD ready for prime time?
The promise of MD utility and the lack of timely 
alternatives have encouraged many researchers to consider 
MD as a surrogate for risk of BC events [97] and to set 
it as a secondary [98, 99] or even as a primary endpoint 
[100] in clinical trials including those evaluating AIs in 
the preventive setting [101], but is this confidence in the 
potential of MD change as a prediction tool justified?
The potential for MD to guide BC intervention 
has long been recognised [102]. As opposed to tissue 
and circulating biomarkers [103], MD is particularly 
appealing since it; 1) significantly correlates with both BC 
risk and outcomes, 2) significantly changes in response 
to some endocrine manipulations, 3) is non-invasive, and 
4) may be easily incorporated in the routine care already 
employed in screening and follow up of BC; thereby, 
minimising additional cost. However, a cancer biomarker 
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should not be introduced into clinical utility before it has 
been validated and before methods and protocols have 
been optimised for effective widespread usage. 
For predictive markers that may change treatment 
decisions, validation has to be rigorous as described by 
Prentice et al [104] and subsequently emphasized by the 
Boyd group [105, 106]. The National Cancer Institute 
of USA has outlined a strategy for biomarker discovery 
and development consisting of three phases. Phase I 
incorporates biomarker discovery, assay development 
and initial small pilot studies, all relatively well covered 
for MD in BC. Phase II undertakes the study of large 
independent retrospective cohorts, as reviewed here (Table 
3). Phase III involves both the retrospective analysis 
of material or data from prospective clinical trials as 
reported here for the IBIS I primary prevention study [48] 
moving forward to new prospective clinical trials where 
the biomarker will be employed for decision making in 
the experimental arm and outcomes are compared with 
standard practice in the control arm.
Considering the adjuvant scenario where the 
intuitive utility of MD monitoring is to guide switching 
between SERM and AI, a retrospective analysis of the 
BIG 1 study where large cohorts received treatment 
with AI alone, SERM alone, AI followed by SERM or 
vice versa [107], appears to be well indicated. If patients 
with no significant MD change on initial therapy show 
better outcomes after switching than those with similar 
MD dynamics randomised to remain on the same initial 
therapy, this could pave the way for a prospective trial 
using MD change to tailor therapy type with the potential 
to improve BC outcomes.
Additionally, before MD change can be introduced 
as a predictive biomarker into the clinical practice, some 
more pragmatic knowledge gaps also need to be filled:
1) What MDR threshold best predicts outcome 
improvement?
2) What is the most accurate predicting MD 
parameter i.e. percent density (in terms of area vs. volume) 
vs. absolute measures (e.g. dense area) vs. categorical 
density (in terms of BIRADS vs. Boyd’s vs. Wolf’s 
categories)?
3) What is the best (accurate and feasible) MD 
interpretation method i.e. visual vs. computer assisted vs. 
fully automated methods?
MATERIALS AND METHODS
Relevant literature was identified by an interrogation 
of Embase and Medline electronic databases using the 
Ovid interface. Our strategy consisted of searching in (all 
fields), using keywords extracted from the relevant MeSH 
headings, which were then combined using the Boolean 
operators, leading to the search terms: [(mammographic 
density) AND (receptor modulat* OR arzoxifen* OR 
lasofoxifen* OR raloxifen* OR tamoxifen*)] and 
[(mammographic density) AND (aromatase inhibit* OR 
anastrozol* OR letrozol* OR exemestan*)]. Limitations 
applied were: 1) English literature, 2) publication year 
(2000 - current). Full text manuscripts of relevant records 
were assessed for eligibility. Eligible articles were those 
investigating BC risk or outcomes and MD changes in 
relation to ETs in the preventive or adjuvant BC scenarios. 
Additional articles were retrieved either from relevant 
article bibliographies or from Pubmed for the monitoring 
biomarker section. Relevant data from an interim analysis 
of a study by members of our group were also included. A 
total of 107 eligible publications were identified and used 
to construct this review.
CONCLUSIONS
MD change over the ET course, rather than a 
single MD measurement, can predict risk or outcome 
modifications in BC preventive and adjuvant settings with 
certain restrictions. MD reduction is relatively frequent 
for patients on tamoxifen, with reasonable evidence 
in both primary and secondary preventative settings 
that this correlates with risk reduction. The situation 
with other SERMs and AIs is unclear with further, 
larger studies required. Analyses in this area should 
take account of the potential effects of patients entering 
menopause or stopping HRT, which may confound results. 
Development of MD as a biomarker appears relatively 
well advanced through the later Phase II or early Phase 
III stages of the NCI biomarker development scheme. 
Retrospective analysis of prospective trials and subsequent 
employment of MD in future prospective randomised 
trials is now required to advance the field towards clinical 
utility. Additionally, studies are also needed to fill the 
aforementioned knowledge gaps to define the optimum 
elements of MD to assess and the method of measurement 
to employ, to ensure reproducibility across health systems. 
Further research, exploring the pathobiological relation 
between MD and BC may also assist in new target 
discovery and the consequent development of novel 
therapeutics. 
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